Golden
Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics is a biotechnology and pharmaceutical company developing therapeutics for Alzheimer’s disease and other neurodegenerative disorders that is headquartered in Pittsburgh, Pennsylvania in 2007 by Gilbert Rishton and Susan Catalano.

Cognition Therapeutics is a biotechnology and pharmaceutical company that was founded by Gilbert Rishton and Susan Catalano in 2007, and is headquartered in Pittsburgh, Pennsylvania.



Cognition Therapeutics engages in drug development and discovery to develop novel approaches to the treatment of central nervous system disorders. The companies treatment approach to central nervous system disorders, such as Alzheimers disease and other neurodegenerative disorders, is to prevent the accumulation of toxic proteins associated with central nervous system disorders through the discovery and application of small molecule drug therapies. 

Timeline

Funding rounds

3 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Alexander Craig

Investor



Alicia Syrett

Investor



Anne Estabrook

Investor



David Hunt/Hunt Technology Ventures, L.P.

Investor



Deb Gerardi Kemper

Investor



Elinor MacKinnon

Investor



Gilbert Rishton

Chief Medicinal Chemistry Advisor



Hank Safferstein

Senior Vice President



Hans Hugh Miller

Investor



Jacqueline Dedell

Investor



Jean Peters

Investor



Jenevra Georgini

Investor



John B Goodrich

Investor



Kat Dave

Investor



Kenneth Moch

President & CEO



Marc Brands

Investor



Marcia Rick Dawood

Investor



Marjorie Kaufman, CFA

Investor



Michael Grundman

Chief Medical Advisor



Robert Windsor

Investor



Squirrel Hill Ventures

Investor



Stephen DiPalma

Chief Financial Officer



Susan Catalano

Founder & Chief Science Officer



Further reading

Title
Author
Link
Type
Date

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer's Disease

Cognition Therapeutics, Inc.

Web



Cognition Therapeutics making strides in Alzheimer's research - Ben Franklin Technology Partners of Pennsylvania

Ben Franklin Technology Parters

Web



Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of ElaytaTM in Patients with Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics, Inc.

Web



Documentaries, videos and podcasts

Title
Date
Link

Dr. Susan Catalano of Cognition Therapeutics | Bootstrapping in America

July 18, 2018

Companies

Company
CEO
Location
Products/Services









References